Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers.

Protein misfolding and aggregation are thought to underlie the pathogenesis of many amyloid diseases, such as Alzheimer and Parkinson diseases, whereby a stepwise protein misfolding process begins with the conversion of soluble protein monomers to prefibrillar oligomers and progresses to the formation of insoluble amyloid fibrils. Drusen are extracellular deposits found in aging eyes and in eyes afflicted with age-related macular degeneration (AMD). Recent characterizations of drusen have revealed protein components that are shared with amyloid deposits. However, characteristic amyloid fibrils have thus far not been identified in drusen. In this study, we tested the hypothesis that nonfibrillar oligomers may be a common link in amyloid diseases. Oligomers consisting of distinct amyloidogenic proteins and peptides can be detected by a recently developed antibody that is thought to recognize a common structure. Notably, oligomers exhibit cellular toxicity, which suggests that they play a role in the pathogenesis of neurodegenerative diseases. Through use of the anti-oligomer antibody, we came to observe the presence of nonfibrillar, toxic oligomers in drusen. Conversely, no reactivity was observed in age-matched control eyes without drusen. These results suggest that amyloid oligomers may be involved in drusen biogenesis and that similar protein misfolding processes may occur in AMD and amyloid diseases.

[1]  G. Malek,et al.  Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. Malek,et al.  Apolipoprotein E allele-dependent pathogenesis: A model for age-related retinal degeneration , 2005 .

[3]  M. Bucciantini,et al.  Insights into the molecular basis of the differing susceptibility of varying cell types to the toxicity of amyloid aggregates , 2005, Journal of Cell Science.

[4]  R. T. Smith,et al.  A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Edwards,et al.  Complement Factor H Polymorphism and Age-Related Macular Degeneration , 2005, Science.

[6]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[7]  J. Gilbert,et al.  Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration , 2005, Science.

[8]  A. Donald,et al.  The binding of thioflavin-T to amyloid fibrils: localisation and implications. , 2005, Journal of structural biology.

[9]  H. Levine Alzheimer’s β-peptide oligomer formation at physiologic concentrations , 2004 .

[10]  R. Kayed,et al.  Permeabilization of Lipid Bilayers Is a Common Conformation-dependent Activity of Soluble Amyloid Oligomers in Protein Misfolding Diseases* , 2004, Journal of Biological Chemistry.

[11]  J. Saffitz,et al.  Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Lindquist,et al.  Hsp104 Catalyzes Formation and Elimination of Self-Replicating Sup35 Prion Conformers , 2004, Science.

[13]  M. Carty,et al.  Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. , 2004, Diabetes.

[14]  J. Kelly,et al.  Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Alexander J. Rivest,et al.  Characterization of β amyloid assemblies in drusen: The deposits associated with aging and age-related macular degeneration , 2004 .

[16]  Alexander J. Rivest,et al.  Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. , 2004, Experimental eye research.

[17]  Ronald Klein,et al.  The epidemiology of age-related macular degeneration. , 2004, American journal of ophthalmology.

[18]  H. Levine Alzheimer's beta-peptide oligomer formation at physiologic concentrations. , 2004, Analytical biochemistry.

[19]  P. Lansbury,et al.  Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. , 2003, Annual review of neuroscience.

[20]  C. Finch,et al.  Self-assembly of Aβ1-42 into globular neurotoxins , 2003 .

[21]  Eiji Sakurai,et al.  An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice , 2003, Nature Medicine.

[22]  P. Mehta,et al.  Humoral immune response to fibrillar β-amyloid peptide , 2003 .

[23]  Geoffrey P Lewis,et al.  Drusen-associated degeneration in the retina. , 2003, Investigative ophthalmology & visual science.

[24]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[25]  G. Krafft,et al.  In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis* , 2003, The Journal of Biological Chemistry.

[26]  J. Wegiel,et al.  Humoral immune response to fibrillar beta-amyloid peptide. , 2003, Biochemistry.

[27]  C. Finch,et al.  Self-assembly of Abeta(1-42) into globular neurotoxins. , 2003, Biochemistry.

[28]  Claudio Soto,et al.  Unfolding the role of protein misfolding in neurodegenerative diseases , 2003, Nature Reviews Neuroscience.

[29]  Masaru Miyagi,et al.  Drusen proteome analysis: An approach to the etiology of age-related macular degeneration , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Kirkitadze,et al.  Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies , 2002, Journal of neuroscience research.

[31]  P. Lansbury,et al.  Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. , 2002, Biochemistry.

[32]  Alexander J. Rivest,et al.  The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[34]  L. V. Johnson,et al.  Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. , 2001, Experimental eye research.

[35]  J. Bureš,et al.  Specific spatial learning deficits become severe with age in β-amyloid precursor protein transgenic mice that harbor diffuse β-amyloid deposits but do not form plaques , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Robert F. Mullins,et al.  An Integrated Hypothesis That Considers Drusen as Biomarkers of Immune-Mediated Processes at the RPE-Bruch's Membrane Interface in Aging and Age-Related Macular Degeneration , 2001, Progress in Retinal and Eye Research.

[37]  C. Finch,et al.  Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? , 2001, Trends in Neurosciences.

[38]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[39]  S. Russell,et al.  Drusen associated with aging and age‐related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[41]  B S Hawkins,et al.  Epidemiology of age-related macular degeneration. , 1999, Molecular vision.

[42]  G. Hageman,et al.  Human Ocular Drusen Possess Novel Core Domains with a Distinct Carbohydrate Composition , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[43]  L. D. Del Priore,et al.  Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. , 1999, Survey of ophthalmology.

[44]  R. Nicoll,et al.  Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Veerle Baekelandt,et al.  Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain* , 1999, The Journal of Biological Chemistry.

[46]  S. Russell,et al.  Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  H. Levine Quantification of beta-sheet amyloid fibril structures with thioflavin T. , 1999, Methods in enzymology.

[48]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[49]  C. Blake,et al.  The structure of amyloid fibrils by electron microscopy and X-ray diffraction. , 1997, Advances in protein chemistry.

[50]  M. Tso,et al.  Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina. , 1995, Investigative ophthalmology & visual science.

[51]  H. Puchtler,et al.  ON THE BINDING OF CONGO RED BY AMYLOID , 1962 .